Global Antibody Drug Conjugates (ADCs) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Antibody Drug Conjugates (ADCs) market size will reach US$ million by 2031.

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.

Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.

LPI (LP Information)' newest research report, the “Antibody Drug Conjugates (ADCs) Industry Forecast” looks at past sales and reviews total world Antibody Drug Conjugates (ADCs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody Drug Conjugates (ADCs) sales for 2025 through 2031. With Antibody Drug Conjugates (ADCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody Drug Conjugates (ADCs) industry.

This Insight Report provides a comprehensive analysis of the global Antibody Drug Conjugates (ADCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody Drug Conjugates (ADCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody Drug Conjugates (ADCs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody Drug Conjugates (ADCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody Drug Conjugates (ADCs).

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody Drug Conjugates (ADCs) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology

Segmentation by Application:
Hospital
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver. Show more